STM JOURNALS

Research & Reviews: A Journal of
Toxicology

ISSN: 2231-3834 (Online)
ISSN: 2349-1264 (Print)
Volume 16, Issue 1, 2026
January–April
DOI (Journal): 10.37591/RRJOT

https://journals.stmjournals.com/rrjot/

Research RRJOT

Prospective Evaluation of the Optimal Concentration and Effect of Epinephrine as an Adjuvant to Local Anesthetics for Prolonging Block Duration and Reducing Systemic Toxicity in Outpatient Surgery

Pratul[1,*], Deepanshu Sharma[2], Masrata Gull[3]

Abstract

Purpose: *To evaluate the optimal concentration and effect of epinephrine as an adjuvant to local anesthetics for prolonging block duration and reducing systemic toxicity in outpatient surgery.* ***Methods:*** *The study involved a randomized double-blind clinical trial on 80 adult patients awaiting day-care extremity surgery. The patients were randomly assigned to two groups of equal size. One group, Group E, was given the local anesthetic agent along with epinephrine as an adjuvant, while the other group, Group C, was given the local anesthetic agent without the adjuvant. The outcome measures evaluated in the study included the duration of the anesthetic block and the occurrence of systemic toxicity or other adverse effects associated with the anesthetic agents. The secondary outcome measures included the measurement of the hemodynamic parameters such as the patient's heart rate and blood pressure, the evaluation of the intraoperative and postoperative stability of the patients, and the evaluation of the patient's recovery profiles.* ***Results:*** *Epinephrine significantly increased block duration (mean 180 min vs 130 min, $p < 0.001$), reduced nausea/vomiting and increased bradycardia/hypotension rates. No serious adverse events occurred.* ***Conclusions:*** *Epinephrine is effective for prolonging anesthesia block with a manageable safety profile when correctly dosed.*

Keywords: Adjuvants, epinephrine, local anesthetics, nerve block, outpatient surgery, randomized controlled trial, regional anesthesia, systemic toxicity

INTRODUCTION

Regional anesthesia has become an essential component of pain management for outpatient surgery, providing targeted neural blockade, rapid recovery, and significantly reduced reliance on systemic opioids [1–3]. Local anesthetic agents, such as lidocaine, bupivacaine, and mepivacaine, are commonly used to accomplish this, yet their effectiveness is limited by systemic absorption and the risk of toxicity, particularly during procedures requiring prolonged analgesia [4–6]. To optimize their clinical performance, epinephrine is frequently used as an adjuvant because its vasoconstrictive effects slow systemic uptake of anesthetics, prolong block duration, and reduce chances of intravascular injection [7–10]. Standard concentrations of epinephrine in these mixtures vary widely, most often between 1:100,000 and 1:200,000 (5–10 µg/ml), though the precise optimal concentration balancing efficacy and safety in outpatient practice has not been universally determined [11–13].

***Author for Correspondence**
Pratul
E-mail: pratulsaini8@gmail.com

[1]Student, Department of Anesthesia, Maharishi Markandeshwar Institute of Medical Sciences and Research (MMIMSR), Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India
Assistant Professor, Department of Anesthesia, Maharishi Markandeshwar Institute of Medical Sciences and Research (MMIMSR), Mullana, Ambala, Haryana, India
[3]Student, Department of Anesthesia, Student of Dolphin PG College, Chunni, Kalan, Punjab, India

Received Date: January 10, 2026
Accepted Date: February 01, 2026
Published Date: April 15, 2026

Citation: Pratul, Deepanshu Sharma, Masrata Gull. Prospective Evaluation of the Optimal Concentration and Effect of Epinephrine as an Adjuvant to Local Anesthetics for Prolonging Block Duration and Reducing Systemic Toxicity in Outpatient Surgery. Research & Reviews: A Journal of Toxicology. 2026; 16(1): 64–69p.

High concentrations of epinephrine can cause adverse systemic effects, such as hypertension, tachycardia, and even tissue ischemia, underscoring the importance of understanding patient-specific factors when dosing [14–16], recent pharmacokinetic studies suggest the dose-response relationship of epinephrine with local anesthetic duration is influenced by block type and individual anatomy, but consensus protocols are still evolving [17, 18].

The role of epinephrine as an adjuvant in local anesthetic techniques has been widely recognized, particularly for its ability to reduce the risk of local anesthetic systemic toxicity (LAST). This protective effect is primarily attributed to its vasoconstrictive properties, which limit the systemic absorption of local anesthetic agents from the site of injection. By slowing the rate at which these drugs enter the systemic circulation, epinephrine helps decrease overall drug exposure to vital organs, such as the heart and brain, thereby reducing the likelihood of toxic reactions. Additionally, vasoconstriction at the injection site can prolong the duration of the anesthetic block, improve the quality of analgesia, and reduce the total dose of anesthetic required during surgical procedures.

However, despite these advantages, the clinical evidence regarding the universal benefit of epinephrine remains inconsistent. Variations in outcomes have been reported across different studies due to factors such as the type of local anesthetic used, the concentration of epinephrine administered, differences in peripheral nerve block techniques, and patient-specific physiological responses. In some cases, concerns have also been raised regarding potential cardiovascular effects associated with epinephrine use, particularly in susceptible individuals.

Given these uncertainties and the growing use of regional anesthesia in outpatient and day-care surgical settings, further investigation is necessary to clarify the optimal role of epinephrine as an adjuvant. In this context, the present prospective study aims to evaluate the appropriate concentrations and clinical effects of epinephrine when combined with local anesthetics in outpatient extremity surgeries. The study specifically focuses on determining whether the addition of epinephrine can effectively prolong block duration while simultaneously minimizing the risk of systemic toxicity. By systematically assessing these outcomes, the research seeks to enhance patient safety, optimize anesthetic efficiency, and contribute valuable evidence that may help guide future clinical recommendations and anesthesia practice guidelines [19, 20].

Therefore, this study aims to prospectively evaluate the optimal concentration and effect of epinephrine as an adjuvant to different local anesthetics in outpatient surgery, with specific attention to block duration, systematic toxicity, and patient safety. The findings could help guide clinical practice protocols and address key gaps in anesthetic safety and recovery for the ambulatory patient population.

METHODOLOGY

Study Design and Population

A prospective, randomized, double-blind controlled trial was conducted at a tertiary care hospital to evaluate the effectiveness and safety of the study intervention. Adult patients between 18 and 65 years of age who were classified as American Society of Anesthesiologists (ASA) physical status I–II and scheduled to undergo elective outpatient extremity surgery were considered eligible for inclusion in the study. All participants provided informed consent prior to enrollment. Patients were randomly assigned to the study groups, and both the participants and investigators involved in outcome assessment were blinded to the group allocation to minimize bias.

Several exclusion criteria were applied to ensure patient safety and the reliability of the results. Patients with a known allergy or hypersensitivity to any of the study drugs were excluded. Additionally, individuals with significant cardiovascular disorders, psychiatric illnesses, or other serious systemic conditions were not included. Patients who had recently used central nervous system depressant medications or substances that could influence anesthetic response were also excluded from the study to avoid confounding effects on the outcomes.

Randomization and Intervention

80 patients were randomized in blocks into Group E (epinephrine 1:200,000 with local anesthetics) and Group C (local anesthetic only), 40 per group. Allocation sequences were generated by computer and maintained by pharmacy blinding.

Outcome Measures

Primary

- Block duration (min) from onset to first pain.
- Systemic toxicity (LAST criteria), adverse events incidence.

Secondary

- Hemodynamic variables (HR, MAP).
- Sedation and recovery scores.

Statistical Analysis

Continuous variables were checked for normality (Kolmogorov-Smirnov test); means were compared with independent t-tests, categorical data with chi-square or Fisher's exact tests. Statistical significance was set at $p < 0.05$.

Data Collection

Demographic data, clinical factors, block characteristics, hemodynamics, and adverse events were systematically recorded by blinded observers. Data integrity checks and validation were performed prior to analysis.

RESULTS

Study Population and Baseline

There were no protocol deviations or withdrawals. Demographics were comparable across groups (mean age Group E 38.7±12.1, Group C 40.4±11.7; 21 males/19 females per group).

Block Duration

Mean Anesthesia Block Duration

- *Group E (Epinephrine):* 180 ± 22 min.
- *Group C (Control):* 130 ± 21 min ($p < 0.001$) as shown in Figure 1.



Figure 1. Mean anesthesia block duration by group.

Adverse Events

- *Group E:* Hypotension (6), bradycardia (12), nausea (2), vomiting (0), headache (2).
- *Group C:* Hypotension (2), bradycardia (2), nausea (6), vomiting (4), headache (1) (Figure 2).



Figure 2. Distribution of adverse events in epinephrine and control groups.

Hemodynamic Trends (Table 1)

Table 1. Mean heart rate at different time points in the epinephrine (Group E) and Control (Group C) groups.

Timepoint	Group E (epinephrine)	Group C (control)
Baseline	78	79
Induction	75	78
End of Operation	72	80
30 min Post-op	74	81
7 days Post-op	76	80

Heart rate remained lower in Group E perioperatively, with no severe bradycardia or tachycardia observed shown in Figure 3.



Figure 3. Heart rate trends over time.

Recovery and Toxicity

No cases of severe LAST or allergic reaction were observed. All adverse events were transient and resolved with standard management.

DISCUSSION

This randomized trial demonstrates that epinephrine used as an adjuvant for local anesthetics in outpatient surgery significantly prolongs anesthesia duration and reduces nausea/vomiting, at the cost of increased mild bradycardia/hypotension. The absence of severe complications observed during the study indicates that the procedure is relatively safe when appropriate dosing guidelines and careful patient monitoring are followed. None of the participants experienced serious systemic toxicity, major cardiovascular instability, or other life-threatening adverse events throughout the perioperative and postoperative periods. This suggests that the anesthetic technique, when administered under controlled clinical conditions by trained professionals, can be effectively utilized without significantly increasing patient risk. Continuous monitoring of vital parameters, such as heart rate, blood pressure, and oxygen saturation, further contributes to maintaining patient safety and early detection of any physiological alterations.

These findings provide supportive evidence for the potential incorporation of epinephrine as an adjuvant in day-care anesthesia protocols. The addition of epinephrine appears to enhance the duration and quality of the anesthetic block while maintaining a manageable safety profile. Although mild physiological effects, such as transient changes in heart rate or blood pressure may occur, they are typically controllable and clinically insignificant when proper monitoring is implemented. Therefore, the use of epinephrine may help improve anesthetic efficiency, prolong analgesia, and optimize patient recovery in ambulatory surgical settings while maintaining a favorable risk–benefit balance.

Future extensions should examine dosing in special populations (elderly, pediatric) and further refine hemodynamic risk mitigation. Methodological strengths include robust blinding, comprehensive outcome assessment, and replicability. Limitations include single-center design and moderate sample size.

CONCLUSION

Epinephrine is an effective adjuvant for prolonging anesthesia block in outpatient surgery, with predictable, manageable hemodynamic effects. Personalized dosing and vigilant monitoring remain vital for optimal clinical outcomes. These data support updated guidelines for day care anesthesia practice.

REFERENCES

1. Swain A, Nag DS, Sahu S, Samaddar DP. Adjuvants to local anesthetics: Current understanding and future trends. World J Clin Cases. 2017;5(8):307–323. doi: 10.12998/wjcc.v5.i8.307.
2. Sharma A, Kaur K, Singh PM. Equal mixture of 2% lidocaine with adrenaline and 0.5% bupivacaine for minor outpatient surgery. Reg Anesth Pain Med. 2024;49(2):112–118.
3. Brummett CM, Norat MA, Palmisano JM, Lydic R. Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. Anesthesiology. 2008;109(3):502–511. doi:10.1097/ALN.0b013e318182c2f3.
4. Becker DE, Reed KL. Local anesthetics: Review of pharmacological considerations. Anesth Prog. 2012;59(2):90–101.
5. Neal JM, Woodward CM, Harrison TK. The American Society of Regional Anesthesia and Pain Medicine checklist for treatment of local anesthetic systemic toxicity. Reg Anesth Pain Med. 2025;50(1):12–20.
6. Kahn CH, Peden CJ. Use of local anesthetics with an epinephrine additive on skin and soft tissue outcomes. J Dermatol Surg. 2024;50(4):425–432.
7. Butterworth JF, Mackey DC, Wasnick JD. Infiltrative administration of local anesthetic agents. In: Morgan & Mikhail's Clinical Anesthesiology. 6th ed. New York: McGraw-Hill; 2022.

8. Denkler KA. A comprehensive review of epinephrine in the finger: To do or not to do. Plast Reconstr Surg. 2001;108(1):114–124.
9. Kirksey MA, Haskins SC, Cheng J, Liu SS. Local anesthetic peripheral nerve block adjuvants for prolonging analgesia: Systematic qualitative review. PLoS One. 2015;10(9):e0137312.
10. Becker DE, Reed KL. Principles of office anesthesia: Part I. Infiltrative anesthesia. Am Fam Physician. 2002;66(1):91–94.
11. Liu SS, McDonald SB. Current issues in spinal anesthesia. Anesthesiology. 2004;101(1):223–237.
12. Filos KS, Goudas LC, Patroni O, Polyzou V. Hemodynamic and analgesic profile after intrathecal clonidine in humans: A dose-response study. Anesthesiology. 1994;81(3):591–601.
13. Brummett CM, Williams BA. Additives to local anesthetics for peripheral nerve blockade. Anesthesiology. 2011;115(2):466–468.
14. Neal JM, Barrington MJ, Fettiplace MR, Gitman M, Memtsoudis SG. The third American Society of Regional Anesthesia practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2018;43(2):113–123.
15. Neal JM, Mulroy MF, Weinberg GL. Local anesthetic systemic toxicity revisited: A paradigm in evolution. Anesth Analg. 2018;127(1):21–24.
16. Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: A multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564–575.
17. Nashville Anesthesia Professionals. Maximum dose of local anesthesia. Nashville (TN): Nashville Anesthesia Pros; 2025.
18. Chin KJ, Mariano ER, El-Boghdadly K. Local anesthetic dosing for fascial plane blocks to avoid systemic toxicity: A narrative review. Can J Anaesth. 2025;72(1):1–12.
19. El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
20. Gitman M, Barrington MJ. Local anesthetic systemic toxicity: Current perspectives. Local Reg Anesth. 2018;11:35–44.

